AAHI NEWS

Innovations • Global Impact • In The News • Our People

AAHI Hosts the Next Generation of Scientists

AAHI was delighted to host Shoreline Community College biotechnology students for a tour of AAHI facilities to learn more about what goes into developing a vaccine product from the laboratory bench to manufacturing for human clinical trials. 

INNOVATIONS

The latest scientific breakthroughs at AAHI.

Make your products accessible to those who need them most. Collaborate with AAHI.

GLOBAL IMPACT

MARCH 2023

Collaboration across communities.

Explore AAHI's different areas of impact.

Seattle, USA

AAHI Partners with the Department of Defense to Develop a Nasal Spray that Could be Broadly Protective Against a Wide Spectrum of Respiratory Viruses

AAHI is awarded $3 million to develop an intranasal pan-viral countermeasure against respiratory viruses. AAHI scientists will develop a prototype nasal spray using AAHI's novel formulation of two immune-stimulating adjuvants (TLR agonists) as a pre-exposure prophylactic against infectious respiratory diseases, including novel viruses and newly emerging variants of existing viruses. AAHI scientists will test the nasal spray against pandemic influenza and Nipah virus in preclinical studies. If successful, the activities under the award will support rapid initiation of Phase 1 clinical trials in humans.

April 3-6

Booth #805

Washington D.C.

AAHI Attends the World Vaccine Congress 2023

We look forward to participating in the most important vaccine event of the year. Our team would love to meet with you - stop by our booth #805 to learn more about AAHI's immune-enhancing platform technologies and how they enable equitable access to health solutions around the world.

Help us make impossible vaccines possible.

IN THE NEWS

By Anthony King

Chemistry World

Shark-derived squalene has been used in hundreds of millions of doses of vaccine, including for flu and Covid-19 and is in candidate vaccines for tuberculosis and malaria. "Our vision is to develop next generation vaccines, whether for influenza or Covid, using such compounds," Christopher Fox tells Chemistry World, "Additional preclinical work in different animal models is needed to establish protective efficacy and safety."

OUR PEOPLE

Collaboration across communities.

Explore our different areas of impact.

Openings and Opportunities

Biotech Manufacturing

The Quality Assurance Associate I/II will be responsible for workforce assessments, providing training to new employees, producing and approving documentation and progress reports, and collaborating with colleagues to ensure everything is running smoothly and complies with company policies and regulations.

Biotech Manufacturing

The Quality Control Associate I/II will be responsible for performing analytical tests, gathering and assessing data from those tests, and writing documentation and reports. The candidate will work in quality control laboratories in a GMP Manufacturing setting.

Research

The Associate / Staff Scientist will be responsible for managing and executing formulation development
and stability studies, including collecting, analyzing, reviewing, and reporting bulk antigen and drug
product characterization for multiple projects.

Research

The Associate / Staff Scientist will be responsible for performing assay development, optimizations and
validations, preparation of blood specimens for ex vivo assays under BSL 2 conditions, performing a
variety of immunological assays, and assisting in drafting manuscripts.

Research

The Senior Scientist joining our RNA vaccine team will be responsible for broadening the applications of
AAHI's RNA vaccine platform to a wide range of infectious disease and oncology targets.

Learn more about our formulation technology

We partner with biotech leaders to develop vaccines and more.

Synthetic TLR4 ligand in squalene nanoemulsion

Synthetic TLR4 ligand in QS- 21 containing liposome

Synthetic TLR4 ligand in aqueous formulation

Dual agonist containing both TLR4 and TLR7/8 ligands

2nd-Gen synthetic TLR4 ligand
in squalene nanoemulsion

2nd-Gen synthetic TLR4 ligand
in QS-21 containing liposome

2nd-Gen synthetic TLR4 ligand
in aqueous formulation

Alum nanoparticle formulation, customized particle size

Synthetic TLR7/8 ligand in
squalene nanoemulsion

Synthetic TLR7/8 ligand
adsorbed to aluminum

Synthetic TLR7/8 ligand in
aqueous formulation

Nanostructured lipid carrier

See how our formulations are being used.

Follow AAHI

Sign up to stay in touch!

Get the latest news and updates in your inbox every month and learn more about how our scientists are developing equitably accessible vaccines and therapeutics for people who most need them.